Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: CI stock price vs COST: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at COST's multiple
Needs COST P/E.
Implied fair value · at CI's multiple
Needs CI P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
The Cigna Group · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
COSTCO WHOLESALE CORP /NEW · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
UNITEDHEALTH GROUP INC
CI vs UNH
CVS HEALTH Corp
CI vs CVS
HUMANA INC
CI vs HUM
CENTENE CORP
CI vs CNC
WEST PHARMACEUTICAL SERVICES INC
CI vs WST
BAXTER INTERNATIONAL INC
CI vs BAX
Walmart Inc.
CI vs WMT
TARGET CORP
CI vs TGT
KROGER CO
CI vs KR
DOLLAR GENERAL CORP
CI vs DG
AMAZON COM INC
CI vs AMZN
HOME DEPOT, INC.
CI vs HD
Edwyn research
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe CI can sustain faster revenue growth while improving ROIC and reducing leverage, then CI may deserve a higher multiple and offers attractive relative value because it already trades far below COST on P/E and P/S; otherwise, COST’s premium looks justified by its much stronger capital efficiency and lower balance-sheet risk.
CI trades at a large discount to COST on both earnings and sales multiples, with P/E at 12.6x versus 52.3x and P/S at 0.3x versus 1.5x. The valuation gap is also reflected in EV/EBITDA at 8.9x for CI versus 37.2x for COST, suggesting the market is assigning COST a much richer quality premium.
Supporting Metrics
